<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="126">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322528</url>
  </required_header>
  <id_info>
    <org_study_id>47817</org_study_id>
    <nct_id>NCT02322528</nct_id>
  </id_info>
  <brief_title>Evaluation of Ocular Surface Inflammatory Mediators Effected by Lotemax</brief_title>
  <official_title>Evaluation of Ocular Surface Inflammatory Mediators and Ocular Surface Metrology Effected by Lotemax</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Rochester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bausch &amp; Lomb Incorporated</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Rochester</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effects of an anti-inflammatory drug (Lotemax®)
      on the surface of the eye and tear film (a film that coats the eye which is made up of oil
      and water).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Ocular Surface Temperature of Both Eyes</measure>
    <time_frame>baseline, 30 minutes, week 1, week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Lotemax® is an FDA-approved ophthalmic suspension for the treatment of steroid-responsive inflammatory conditions which include dry eye associated ocular surface inflammation. Lotemax® will serve as a vehicle to study the changes in the inflammatory mediators on the surface of the eye as well as collect the inflammatory mediators for laboratory analysis, utilizing Luminex instrumentation and standard ELISA assays.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Visual Quality</measure>
    <time_frame>baseline, 30 minutes, week 1, week 2</time_frame>
    <safety_issue>No</safety_issue>
    <description>Using a Shack Hartmann wavefront sensor, measured root mean square of wavefront aberrations caused by dynamic tear film changes.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Sjogren's Disease</condition>
  <arm_group>
    <arm_group_label>Administration of Lotemax</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Administration of Lotemax</intervention_name>
    <description>An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.</description>
    <arm_group_label>Administration of Lotemax</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          -  Age 50-70

          -  Diagnosed with Sjogren's Disease

          -  Good general health (defined by medication use that has not changed within the last 2
             months and the absence of medical conditions that are deemed confounding to the data
             as determined by the PI)

          -  Ability to give informed consent

          -  Willing to spend time for the study; approximately one hour for a screening visit and
             between 60-90 minutes for each of the measurement visits

          -  Either gender

          -  Any racial or ethnic origin

        EXCLUSION CRITERIA:

          -  Use of any prescription ocular medication (such as but not limited to, glaucoma
             medications and Restasis) used within 14 days of the screening visit or started prior
             to the measurement visit(s).

          -  Current acute eye disease that affects the surface of the eye such as, but not
             limited to blepharitis, ocular allergy, and infection.

          -  Subjects who have had cataract surgery less than one year ago

          -  Use of soft or hard contact lenses.

          -  Female subjects may not be pregnant or lactating (subjects will be asked to
             self-report these conditions).

          -  Inability to provide analyzable data
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James V Aquavella, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Rochester</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Flaum Eye Institute at the University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <lastchanged_date>September 17, 2015</lastchanged_date>
  <firstreceived_date>April 16, 2014</firstreceived_date>
  <firstreceived_results_date>September 17, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Rochester</investigator_affiliation>
    <investigator_full_name>James V. Aquavella, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Non-invasive instruments</keyword>
  <keyword>Environment</keyword>
  <keyword>Wavefront</keyword>
  <keyword>Placido Disk</keyword>
  <keyword>Ellipsometer</keyword>
  <keyword>Thermal Imaging</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sjogren's Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Loteprednol etabonate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Administration of 0.5% Lotemax</title>
          <description>An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Administration of Lotemax</title>
          <description>An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="56.7" spread="4.92"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="9"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="10"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Ocular Surface Temperature of Both Eyes</title>
        <description>Lotemax® is an FDA-approved ophthalmic suspension for the treatment of steroid-responsive inflammatory conditions which include dry eye associated ocular surface inflammation. Lotemax® will serve as a vehicle to study the changes in the inflammatory mediators on the surface of the eye as well as collect the inflammatory mediators for laboratory analysis, utilizing Luminex instrumentation and standard ELISA assays.</description>
        <time_frame>baseline, 30 minutes, week 1, week 2</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Administration of 0.5% Lotemax</title>
            <description>An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Ocular Surface Temperature of Both Eyes</title>
            <description>Lotemax® is an FDA-approved ophthalmic suspension for the treatment of steroid-responsive inflammatory conditions which include dry eye associated ocular surface inflammation. Lotemax® will serve as a vehicle to study the changes in the inflammatory mediators on the surface of the eye as well as collect the inflammatory mediators for laboratory analysis, utilizing Luminex instrumentation and standard ELISA assays.</description>
            <units>degrees celcius</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.95" spread="0.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>30 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="34.3" spread="0.13"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>week 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.93" spread="0.12"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="33.95" spread="0.13"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Visual Quality</title>
        <description>Using a Shack Hartmann wavefront sensor, measured root mean square of wavefront aberrations caused by dynamic tear film changes.</description>
        <time_frame>baseline, 30 minutes, week 1, week 2</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Administration of 0.5% Lotemax</title>
            <description>An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="10"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Visual Quality</title>
            <description>Using a Shack Hartmann wavefront sensor, measured root mean square of wavefront aberrations caused by dynamic tear film changes.</description>
            <units>microns</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>baseline</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.48" spread="0.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>30 minutes</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.54" spread="0.04"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>week 1</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.49" spread="0.08"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>week 2</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="0.48" spread="0.04"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Administration of 0.5% Lotemax</title>
          <description>An FDA approved drug (Lotemax) will be administered to both eyes to induce an inflammatory mediated response.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. James V. Aquavella</name_or_title>
      <organization>University of Rochester</organization>
      <phone>585-276-7439</phone>
      <email>rick_barrett@urmc.rochester.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
